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Functional Characterization of the Osteoarthritis Genetic
Risk Residing at ALDH1A2 Identifies rs12915901 as
a Key Target Variant
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Objective. To identify the functional single-
nucleotide polymorphisms (SNPs) and mechanisms con-
ferring increased risk of hand osteoarthritis (OA) at the
ALDH1A2 locus, which is a retinoic acid regulatory
gene.
Methods. Tissue samples from 247 patients with
knee, hip, or hand OA who had undergone joint surgery
were included. RNA-sequencing analysis was used to
investigate differential expression of ALDH1A2 and
other retinoic acid signaling pathway genes in cartilage.
Expression of ALDH1A2 in joint tissues obtained from
multiple sites was quantified using quantitative reverse
transcription–polymerase chain reaction. Allelic expres-
sion imbalance (AEI) was measured by pyrosequencing.
The consequences of ALDH1A2 depletion by RNA inter-
ference were assessed in primary human chondrocytes.
In silico and in vitro analyses were used to pinpoint
which, among 62 highly correlated SNPs, could account
for the association at the locus.
Results. ALDH1A2 expression was observed
across multiple joint tissue samples, including osteo-
chondral tissue from the hand. The expression of
ALDH1A2 and of several retinoic acid signaling genes
was different in diseased cartilage compared to non-
diseased cartilage, with ALDH1A2 showing lower levels
in OA cartilage. Experimental depletion of ALDH1A2
resulted in changes in the expression levels of a number
of chondrogenic markers, including SOX9. In addition,
reduced expression of the OA risk–conferring allele was
witnessed in a number of joint tissues, with the strongest
effect in cartilage. The intronic SNP rs12915901 recapitu-
lated the AEI observed in patient tissues, while the Ets
transcription factors were identified as potential media-
tors of this effect.
Conclusion. The ALDH1A2 locus seems to in-
crease the risk of hand OA through decreased expression
of ALDH1A2 in joint tissues, with the effect dependent on
rs12915901. These findings indicate a mechanism that
may now be targeted to modulate OA risk.
Osteoarthritis (OA) is a common age-related
disease that is characterized by the focal loss of carti-
lage, and that is accompanied by pathologic alterations
to additional joint tissues (1). There are no disease-
modifying drugs for OA, with arthroplasty of the hips
and knees being a common procedure.
Epidemiologic studies have reported an OA heri-
tability of >40% at individual skeletal sites (2), while data
sets from candidate-gene and genome-wide association
studies have revealed that OA is polygenic, with the evi-
dence indicating that there is no risk-conferring loci of
large singular impact. As such, the disease is genetically
complex and multifactorial.
Supported by Arthritis Research UK (grant 20771 and Centre
for OA Pathogenesis grant 20205), the Medical Research Council, the
MRC–Arthritis Research UK Centre for Integrated Research into
Musculoskeletal Ageing, and the European Union under the Seventh
Framework Program (grant 305815; project D-BOARD). Funds to
assist recruitment of patients and processing of tissue were provided by
the NIHR Newcastle Biomedical Research Centre and awarded to the
Newcastle upon Tyne NHS Foundation Trust and Newcastle University.
1Colin Shepherd, PhD, Andrew J. Skelton, MSc, Jennifer
Combe, BSc, Harrison Threadgold, MSc, Louise N. Reynard, PhD,
John Loughlin, PhD: Newcastle University, Newcastle upon Tyne,
UK; 2Dongxing Zhu, PhD: Newcastle University, Newcastle upon
Tyne, UK, and Guangzhou Institute of Cardiovascular Disease, The
Second Affiliated Hospital, and Guangzhou Medical University,
Guangzhou, China; 3Linyi Zhu, PhD, Tonia L. Vincent, MD, PhD:
Arthritis Research UK Centre for OA Pathogenesis, University of
Oxford, Oxford, UK; 4Paul Stuart, FRCS: Newcastle University
Teaching Hospitals NHS Trust, Freeman Hospital, Newcastle upon
Tyne, UK.
Drs. Shepherd and Zhu contributed equally to this work.
Address correspondence to Colin Shepherd, PhD, or John
Loughlin, PhD, Institute of Genetic Medicine, Newcastle University,
International Centre for Life, Newcastle upon Tyne NE2 4HH, UK.
E-mail: colin.shepherd@ncl.ac.uk or john.loughlin@ncl.ac.uk.
Submitted for publication December 5, 2017; accepted in
revised form April 26, 2018.
1577
ARTHRITIS & RHEUMATOLOGY
Vol. 70, No. 10, October 2018, pp 1577–1587
DOI 10.1002/art.40545
© 2018 The Authors. Arthritis & Rheumatology published by Wiley Periodicals, Inc. on behalf of
American College of Rheumatology. This is an open access article under the terms of the Creative
Commons Attribution License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited.
To date, the OA loci identified are typically
located within regions of the genome harboring genes
encoding proteins involved in joint development, matu-
ration, or homeostasis and that tend to contribute to
disease susceptibility only at particular skeletal sites
(2–5). An example of this is the hand OA–associated
single-nucleotide polymorphisms (SNPs) in ALDH1A2
(6). ALDH1A2 codes for the enzyme RALDH2, which
synthesizes the morphogen retinoic acid. Studies have
shown that retinoic acid has pivotal roles in the devel-
opment and maintenance of the skeleton, with its effect
mediated at the gene transcriptional level (7,8).
The association of ALDH1A2 with OA risk was
discovered in Icelanders and replicated in cohorts from
the UK and Netherlands in studies using proxy SNPs
rs3204689 and rs4238326. The greatest odds ratio in
the combined analysis was 1.46 for rs3204689 (P = 1.1
9 1011). None of the SNPs that correlate (r2 > 0.8)
with rs3204689 or rs4238326 are nonsynonymous, imply-
ing that the association acts by modulating gene expres-
sion as a quantitative trait locus (eQTL). The presence
of an eQTL operating on ALDH1A2 was confirmed
using the 30-untranslated region (30-UTR) SNP
rs3204689. An average 17.4% excess expression of
ALDH1A2 messenger RNA (mRNA) from the non-risk
G allele, relative to the risk-conferring C allele, was
reported in knee and hip cartilage samples (6). This is
equivalent to a 15% reduction in ALDH1A2 expression
in the presence of the risk allele.
In this study, we aimed to expand the allelic
expression imbalance (AEI) analysis into other synovial
joint tissues and to the trapezium of patients who had
undergone a trapeziectomy due to hand OA. We car-
ried out a broad analysis of the expression of
ALDH1A2 and genes involved in the retinoic acid path-
way. Finally, we performed experiments to identify a
SNP or SNPs in the association signal that recapitulate
the AEI effect observed in patient tissues and which
could, therefore, be functional candidate SNPs.
PATIENTS AND METHODS
Patients. Joint tissue samples were obtained through 2
centers in the UK, Newcastle and Oxford. The Newcastle col-
lection was undertaken essentially as previously described (9).
The Newcastle and North Tyneside Research Ethics Commit-
tee granted ethics approval for the collection. Each donor pro-
vided verbal and written informed consent (REC reference no.
14/NE/1212). Samples were collected from 1) patients with pri-
mary hip or knee OA who had undergone joint replacement
surgery, 2) patients with primary hand OA who had undergone
trapeziectomy, and 3) patients who had undergone hip replace-
ment due to a neck-of-femur (NOF) fracture. For patients with
hand OA, cartilage could not be readily separated from frac-
tured subchondral bone; therefore these samples comprised
subchondral bone with attached cartilage (i.e., osteochondral
samples). Tissue preparation and grinding was performed as
described previously (10).
DNA and RNA were extracted from the cartilage,
bone, and trapezieum samples using TRIzol reagent (Life
Technologies). For the synovium and fat pad, DNA and RNA
were extracted using an E.Z.N.A. DNA/RNA isolation kit
(Omega Biotek, VWR) (11). Primary human chondrocytes
were prepared and cultured as previously reported (12).
The Oxford Musculoskeletal Biobank collection pro-
vided samples of OA trapezium. Patients gave their informed
consent for sample collection (REC reference no. 09/H0606/
11). Trapezium cartilage was dissected from the bone within 2
hours of surgical removal from the joint, and the tissue was
then snap frozen in liquid nitrogen and stored at 80°C. Car-
tilage and bone tissue were ground using a Cryo-Cup Grinder
(Biospec). RNA was extracted from cartilage using an
RNeasy Micro kit (Qiagen). DNA was extracted from the
bone using DNAzol (Thermo Fisher Scientific).
Further details regarding both the Newcastle and
Oxford patients can be found in Supplementary Table 1
(available on the Arthritis & Rheumatology web site at http://
onlinelibrary.wiley.com/doi/10.1002/art.40545/abstract).
Quantitation of gene expression. Synthesis of comple-
mentary DNA (cDNA) and analysis by quantitative reverse
transcription–polymerase chain reaction (qRT-PCR) were per-
formed as described previously (9). Predesigned TaqMan
assays (Integrated DNA Technologies) were used to quantify
expression of the housekeeping genes HPRT1, 18S, and
GAPDH and the target genes COL2A1, COL10A1, SOX9,
ACAN, ADAMTS5, VEGFA, RUNX2, and MMP13. For target
genes ALDH1A2, RARA, RARB, RARG, RXRA, RXRB,
CRABP2, and CYP26B1, primers were designed using the
Roche probe library system (see Supplementary Table 2,
available on the Arthritis & Rheumatology web site at http://
onlinelibrary.wiley.com/doi/10.1002/art.40545/abstract). P val-
ues were calculated using a Mann-Whitney 2-tailed exact test.
RNA-sequencing (RNA-seq) analysis. RNA-seq analy-
sis was performed on the cartilage of 10 patients with hip OA
and 6 patients with NOF fracture (non-OA controls) (the
RNA-seq data have been deposited in the NCBI Gene
Expression Omnibus [accession no. GSE111358]). Quality of
the raw sequencing data was assessed using Fastqc (version
0.11.5) and compiled for experiment-wide context using
MultiQC (version 1.0dev) (13,14). Salmon software (version
0.8.2) was used to quantify raw Fastq files, based on an index
derived from Gencode V24 transcript sequences (15,16).
Salmon was run in sequence and G/C bias correction models,
with 100 bootstraps. Abundance estimations were analyzed in
R (version 3.4.1), and estimates were imported using Tximport
(version 1.4.0) (17–19). Statistical modeling was performed
using DESeq2 (version 1.16.1) (20) to library-scale normalize
the raw counts and fit a negative binomial generalized linear
model. Hypothesis testing was performed using the DESeq2
implementation of the Wald test. Statistical significance of
the analyzed genes was determined on the basis of a false dis-
covery rate–corrected P value of <0.01 and a fold change fil-
ter of 2.
Genotyping. The rs3204689 SNP was genotyped by a
restriction fragment length polymorphism assay. The SNP was
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amplified by PCR using the primers listed in Supplementary
Table 3 (available on the Arthritis & Rheumatology web site at
http://onlinelibrary.wiley.com/doi/10.1002/art.40545/abstract).
The discriminatory enzyme was SfcI (New England Biolabs),
which cuts at the non-risk G allele.
The rs4238326 SNP was genotyped by pyrosequencing
(see Supplementary Table 3 for the primers used). PCR prod-
ucts were analyzed using the PyroMark Q24 MDx platform
(Qiagen), with use of the sequencing primer listed in Supple-
mentary Table 3 and PyroMark Gold Q96 reagents, in accor-
dance with the manufacturer’s instructions.
Determination of allelic expression imbalance (AEI).
AEI at rs3204689 was quantified by pyrosequencing, using the
pyrosequencing methods described above and the PCR and
sequencing primers listed in Supplementary Table 3. Analysis of
the results was performed as described previously (9). P values
were calculated using a Mann-Whitney 2-tailed exact test.
Determination of mRNA stability. Chondrocytes were
isolated from the cartilage of 4 patients with knee OA who
were heterozygous at rs3204689. The cells were seeded in
6-well plates at 400,000 cells per well, and then treated with
5 lg/ml actinomycin D (Sigma-Aldrich) for 0, 4, 8, 12, and
24 hours. Nucleic acid was extracted using TRIzol reagent
(Life Technologies), and expression of ALDH1A2 was measured
by qRT-PCR.
AEI at rs3204689 was assessed by pyrosequencing.
Expression of ALDH1A2 mRNA in the combined group of
patients was compared at each time point relative to time 0.
P values were calculated using a Mann-Whitney 2-tailed exact
test.
RNA interference (RNAi). RNAi was performed in
chondrocytes isolated from the cartilage of 3 patients with
knee OA, essentially as described previously (9). For each
patient, the cells were seeded in each well of a 6-well plate at
a density of 350,000 cells per well. Cells were transfected with
50 nM Dharmacon ON-TARGETplus SMARTpool small
interfering RNA (siRNA) targeted against ALDH1A2 (L-
008118-00) or a nontargeting siRNA as the control (D-
001810-10-20). RNA and protein were extracted concurrently
using the Nucleospin RNA/protein kit (Macherey-Nagel).
Gene expression was assessed by qRT-PCR using cDNA syn-
thesized from RNA extracted from each well, with 5 technical
repeats per analyzed gene. P values were calculated using a
Student’s 2-tailed t-test.
Immunoblotting. For immunoblot analysis of
RALDH2 depletion following RNAi, 10 lg of protein was
resolved on 10% (weight/volume) sodium dodecyl sulfate–
polyacrylamide gel electrophoresis (SDS-PAGE) gels. Blots
were probed with an anti-ALDH1A2 antibody (HPA010022;
Atlas Antibodies) or anti-GAPDH antibody (Cell Signaling
Technology). RALDH2 depletion was quantified using ImageJ
software (21), with RALDH2 values normalized to the levels
of anti-GAPDH. P values were calculated using Student’s 2-
tailed t-test.
For immunoblot analysis of RALDH2 in ground
trapezium bone samples, cellular protein was extracted with
radioimmunoprecipitation assay buffer. Twenty micrograms of
clarified lysate was resolved by SDS-PAGE and immunoblot-
ted as described above.
Luciferase reporter assays. DNA regions surrounding
the 39 SNPs selected for analysis were cloned and used for
luciferase reporter analysis, essentially as described previously
(9). Primer sequences are listed in Supplementary Table 4
(available on the Arthritis & Rheumatology web site at http://
onlinelibrary.wiley.com/doi/10.1002/art.40545/abstract). The cell
lines SW1353 and HEK 293 (both from ATCC) were seeded
at 10,000 cells per well in 96-well plates, and after 24 hours,
they were transfected with the firefly and Renilla luciferase
constructs. P values were calculated using a Mann-Whitney
2-tailed exact test.
Electrophoretic mobility shift assays (EMSAs).
Nuclear protein was extracted from SW1353 and HEK 293
cells as previously described (22). For each allele of each of
the 8 SNPs studied, forward and reverse single-stranded
DY682-labeled oligonucleotides (Eurofins MWG Operon),
spanning 15 bp each side of the SNP (see Supplementary
Table 5, available on the Arthritis & Rheumatology web site
at http://onlinelibrary.wiley.com/doi/10.1002/art.40545/abstract),
were annealed to generate double-stranded probes. EMSAs were
then undertaken as previously described (22). For rs12915901, an
Ets random competitor probe was used as a negative control
(see Supplementary Table 6, available on the Arthritis &
Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.
1002/art.40545/abstract).
RESULTS
Quantitative expression of ALDH1A2 in joint
tissues. We measured ALDH1A2 expression by qRT-
PCR in the cartilage, fat pad, synovium, and trabecular
bone from OA patients who had undergone knee or
hip joint replacement surgery. Expression was also
measured in osteochondral tissue from patients who
had undergone a trapeziectomy. Expression was highest
in the cartilage and lowest in the bone and trapezium.
In fact, the expression of ALDH1A2 was below the
limit of detection (established as a threshold cycle
value of ≥40) in 17 of the 25 bone samples and 2 of
the 8 trapezium samples (Figure 1A).
Having confirmed expression of ALDH1A2
mRNA in the joint tissues, including samples from the
trapezium of patients who underwent a trapeziectomy,
we next confirmed expression of the RALDH2 protein by
immunoblotting of the protein extracted from the trapez-
ium tissue of patients with hand OA (see Supplementary
Figure 1, available on the Arthritis & Rheumatology web
site at http://onlinelibrary.wiley.com/doi/10.1002/art.40545/
abstract).
Using RNA-seq data from the cartilage of OA
patients and that from non-OA controls (i.e.,
age-matched patients with NOF fracture) who had
undergone hip replacement surgery, we characterized
the expression pattern of the ALDH1A2 transcript iso-
forms. The Ensembl database (available at http://www.
ensembl.org/index.html) lists 25 isoforms for this gene,
of which 8 are predicted to be protein coding. Nine of
the 25 isoforms were expressed in the analyzed
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cartilage above a mean transcripts-per-million threshold
of 1, including 4 of the 8 protein-coding isoforms
(Figure 1B) (see also Supplementary Table 7, available
on the Arthritis & Rheumatology web site at http://
onlinelibrary.wiley.com/doi/10.1002/art.40545/abstract).
When assessing expression of all ALDH1A2 isoforms
combined (designated the ALDH1A2 gene in Figure 1B),
there was a 0.3-fold decrease in ALDH1A2 expression in
the OA cartilage compared to the non-OA control carti-
lage (P < 0.01).
Differential expression of RA pathway genes in
OA cartilage. The reduced expression of ALDH1A2 in
OA compared to non-OA cartilage prompted us to
investigate our RNA-seq data for the relative expression
of other genes active in the retinoic acid pathway (see
Supplementary Table 8, available on the Arthritis &
Rheumatology web site at http://onlinelibrary.wiley.
com/doi/10.1002/art.40545/abstract). Of a panel of 13
genes selected as a representative cross-section of the
retinoic acid pathway, and due to their relatively abun-
dant levels of expression, several of these genes were
differentially expressed between OA cartilage and non-
OA control cartilage (Figure 1C). RARRES1, which
codes for retinoic acid receptor responder 1, was one of
the most significantly differentially expressed genes, with
a 2.4-fold decreased expression in OA cartilage (P =
Figure 1. Expression analysis of ALDH1A2 and retinoic acid pathway genes in multiple tissue samples from patients with osteoarthritis (OA). A,
Expression of ALDH1A2 mRNA was measured by quantitative reverse transcription–polymerase chain reaction in OA cartilage, fat pad, synovium,
bone, and trapezium. B, Expression of ALDH1A2 gene and transcript isoforms (designated by their Ensembl database identification [ID] numbers)
was measured in hip cartilage from OA patients and patients with neck-of-femur (NOF) fracture as controls, using RNA-sequencing data. The cat-
egory “ALDH1A2 gene” represents all isoforms combined. C, Expression of a panel of retinoic acid pathway genes was measured in hip cartilage
from OA patients and non-OA NOF controls, using RNA-sequencing data. The data for ALDH1A2 are replotted for comparison. In C, transcripts
per million (TPM) kilobase values are plotted as the log10. P values were calculated using Mann-Whitney 2-tailed exact test in A and Wald test
within the DESeq2 package in B and C. In A, symbols represent individual samples; horizontal lines with bars show the mean  SEM. In B and
C, results are the mean  SEM. * = P < 0.05; ** = P < 0.01; *** = P < 0.001; **** = P < 0.0001.
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6 9 1012). The results of this analysis imply that there
is a widespread differential regulation of the retinoic
acid pathway between OA and non-OA cartilage.
AEI analysis of ALDH1A2. The investigators
who reported the association of OA risk with
ALDH1A2 observed a reduction in expression of the
OA risk–conferring allele of the gene in AEI analysis.
We replicated this observation, detecting an average
reduction of 28% in the expression of the risk C allele
in the cartilage of patients who were heterozygous at
rs3204689 (P < 0.0001), with the majority of patients
demonstrating AEI (Figure 2A).
In our expanded analysis, we observed an aver-
age reduction of 14% in the expression of the risk C
allele in the fat pad (P < 0.0001) (Figure 2B) and a
reduction of 15% in the bone samples (P = 0.001)
Figure 2. Allelic expression imbalance (AEI) analysis of ALDH1A2. A–E and G, AEI analysis of rs3204689 was carried out in osteoarthritis (OA)
patient cartilage (n = 31) (A), fat pad (n = 24) (B), bone (n = 16) (C), synovium (n = 18) (D), trapezium (n = 10) (E), and primary chondrocytes (n = 9)
(G). Plots in the left panels show the risk/non-risk (C/G) allelic ratios, with a ratio of <1 indicating decreased expression of the C allele. The right pan-
els show the mean values for DNA and cDNA from all patients combined, with results represented as box-and-whisker plots, in which the lines within
the box represent the median, the box represents the 25th to 75th percentiles, and the whiskers represent the minimum and maximum values. A mini-
mum of 3 technical repeats were performed for each patient’s DNA and cDNA. P values were calculated using Mann-Whitney 2-tailed exact test. F,
AEI analysis was carried out in 4 OA patients for whom cartilage samples and tissue from at least one other site were available. The broken horizontal
line indicates a C/G ratio of 1, which is indicative of no allelic imbalance. Values are the mean  SD AEI plotted for each individual in each tissue
tested. Individual patients are designated by their anonymized identification (ID) numbers. ** = P < 0.01; **** = P < 0.0001. NS = not significant.
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(Figure 2C), whereas in the synovium, the reduction
was nonsignificant (average reduction 2%; P > 0.05)
(Figure 2D). We observed an average reduction of
18% in the expression of the risk allele in the trapez-
ium (P < 0.01) (Figure 2E). Despite the nonsignificant
AEI observed in synovium samples, there were individ-
uals who did demonstrate clear AEI in the synovium
(patients 88 and 112 in Figure 2D).
The reduction in expression of the OA risk
allele was less profound in these noncartilaginous joint
tissues, as was most clearly demonstrated when we
compared AEI ratios in 4 patients for whom cartilage
tissue and tissue from at least 1 other site from the
same joint could be concurrently analyzed. In each
patient, cartilage showed a larger AEI than that
observed in any of the noncartilaginous tissue samples
(Figure 2F).
It is noteworthy that in a small number of
patients, the OA risk–conferring C allele was expressed
at a higher level, rather than a lower level, than was
the non-risk allele (Figures 2A–E). This was most obvi-
ous in the synovium of patient 97 (Figure 2D) and the
osteochondral trapezium of patient 212 (Figure 2E).
Finally, we assessed AEI stability during tissue
culture by extracting chondrocytes from the knee carti-
lage of 9 OA patients who were heterozygous at
rs3204689, culturing the cells in monolayer for a mini-
mum of 10 days and then undertaking AEI analysis
(Figure 2G). We observed an average reduction of
25% in the expression of the risk allele (P = 0.004),
which is comparable to the reduction seen in OA carti-
lage tissue samples (Figure 2A), thus suggesting that
the AEI is stable during cell division in vitro.
Effect of knockdown of ALDH1A2 on chondro-
cyte gene expression. Having demonstrated that the
OA risk–conferring C allele of rs3204689 is correlated
with decreased expression of ALDH1A2, we next mod-
eled this effect. Chondrocytes were isolated from the
knee cartilage of 3 OA patients, and then cultured in
monolayer and subjected to ALDH1A2 knockdown by
RNAi. Compared to the effects of the scrambled
siRNA control, siRNA targeting ALDH1A2 achieved a
mean knockdown at the ALDH1A2 mRNA level of
89% (P < 0.0001) (Figure 3A), with a 22% reduction
at the protein level (P < 0.05) (Figure 3B).
We next assessed the effect of this knockdown of
ALDH1A2 on the expression of 7 retinoic acid pathway
genes (RARA, RARB, RARG, RXRA, RXRB, CRABP2,
and CYP26B1) and 8 chondrogenic genes (SOX9,
ADAMTS5, MMP13, ACAN, COL2A1, COL10A1,
RUNX2, and VEGFA). Depletion of ALDH1A2 corre-
lated with a significant reduction in the expression of
RARB (P = 0.001), SOX9 (P = 0.002), ADAMTS5 (P =
0.007), ACAN (P = 0.04), and VEGFA (P = 0.004) (Fig-
ures 3C–G). Therefore, in this model system, depletion
of ALDH1A2 transcript and of its protein in OA knee
cartilage had a significant impact on genes that encode
regulators of cartilage homeostasis.
Figure 3. Effects of knockdown of ALDH1A2 in primary chondrocytes from patients with osteoarthritis (OA). A, ALDH1A2 knockdown with
small interfering RNA (siRNA) targeting ALDH1A2 (siALDH1A2) was carried out in cultured knee chondrocytes from 3 OA patients, in compar-
ison to the effects of a nontargeting siRNA control (siControl). ALDH1A2 expression was measured by quantitative reverse transcription–poly-
merase chain reaction. Values represent the mean  SD fold change in expression compared to siControl, with the data combined for the 3
patients. B, Representative results from immunoblotting demonstrate depletion of RALDH2 protein following ALDH1A2 knockdown. GAPDH
was used as a loading control. C–G, The fold change in expression of RARB (C), SOX9 (D), ADAMTS5 (E), ACAN (F), and VEGFA (G) following
ALDH1A2 knockdown, relative to that with the siControl, was assessed in chondrocytes from the 3 OA patients combined. Values are the
mean  SD. P values were calculated using Student’s 2-tailed t-test. * = P < 0.05; ** = P < 0.01; *** = P < 0.001; **** = P < 0.0001.
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Lack of involvement of UTR SNPs in regulating
transcript stability. The 30-UTRs offer binding sites for
microRNAs (miRNAs) that can regulate transcript sta-
bility. The 30-UTR of ALDH1A2 contains 2 SNPs that
correlate with the rs3204689 association signal:
rs3204689 itself and rs9325 (r2 = 0.96 with rs3204689).
A search of TargetScan (http://www.targetscan.org/vert_
71/) revealed that both of these SNPs reside within pre-
dicted miRNA binding sites. In order to assess whether
the eQTL operating on ALDH1A2 was the result of
miRNA-mediated transcript degradation, we measured
AEI in cultured chondrocytes following treatment with
the transcriptional inhibitor actinomycin D. If the ratio
of AEI endures following treatment, this would imply
that the AEI results from differential transcription
between alleles, rather than differential transcript sta-
bility.
We investigated chondrocytes from 4 patients
with knee OA who were heterozygous at rs3204689.
Levels of ALDH1A2 mRNA expression were signifi-
cantly decreased in the chondrocytes after 12 hours (P <
0.01) and 24 hours (P < 0.0001) of actinomycin D treat-
ment, compared to time 0 (Figure 4A), but the allelic
ratio remained stable for the duration of the time course
in each patient’s cells (Figure 4B). These data therefore
support the notion that an effect on transcription, rather
than transcript stability, is the mechanism through which
the association signal impacts on ALDH1A2 expression.
Triage to identify functional candidate SNPs.
We aimed to identify SNPs that correlated with the OA
association signal, and in which the 2 SNP alleles
demonstrated differential transcriptional activity. Such
SNPs would be strong functional candidates responsible
for the AEI. To achieve this, we applied a triage system
that had 3 sequential stages: 1) identification of SNPs
showing a correlation (r2 ≥ 0.8) with either rs3204689
or rs4238326 and that could be predicted in silico to be
potentially functional; 2) luciferase reporter analysis of
both alleles of these SNPs in transformed cell lines;
and 3) further functional characterization by EMSA of
the SNPs that demonstrated AEI in the luciferase anal-
ysis.
SNPs correlated with the OA association signal.
Using HaploReg version 4.1 (http://archive.broadinstitute.
org/mammals/haploreg/haploreg.php), we identified 54
SNPs that strongly correlated with rs3204689 and 8 SNPs
that strongly correlated with rs4238326 (each r2 ≥ 0.8)
(see Supplementary Tables 9 and 10, available on the
Arthritis & Rheumatology web site at http://onlinelibrary.
wiley.com/doi/10.1002/art.40545/abstract). All resided within
the gene body or immediately downstream of ALDH1A2,
and encompassed a 145-kb region.
We screened all 62 of these SNPs, as well as
rs3204689 and rs4238326, for predicted transcriptional
functionality using RegulomeDB (http://www.regulomedb.
org) (for more details on the RegulomeDB scores, see
Supplementary Figure 2, available on the Arthritis &
Rheumatology web site at http://onlinelibrary.wiley.com/
doi/10.1002/art.40545/abstract). This analysis identified 38
positive SNPs (as indicated by the RegulomeDB scores
listed in Supplementary Tables 9 and 10), and these
were taken forward for luciferase analysis. We also
included rs4646563, despite there being no supporting
RegulomeDB data for this SNP, as it resides close to
the CpG dinucleotide cg12031962, which marks an
ALDH1A2 methylation QTL (mQTL) that we described
in a previous report (23). In total, we took forward 39
SNPs for luciferase analysis.
Figure 4. ALDH1A2 transcript stability in osteoarthritis (OA) chon-
drocytes. A, Chondrocytes from 4 OA patients were cultured in the
presence of actinomycin D for 0, 4, 8, 12, or 24 hours and the effects
on ALDH1A2 mRNA expression were assessed by quantitative
reverse transcription–polymerase chain reaction. At each time point,
the mean  SEM ALDH1A2 mRNA expression level in the 4
patients combined was compared to time 0. P values were calculated
using a Mann-Whitney 2-tailed exact test. B, The allelic ratio (C/G)
at rs3204689 was determined by pyrosequencing in the chondrocytes
from the 4 OA patients at each time point. Values are the mean ratio
determined from 6 technical repeats. Individual patients are desig-
nated by their anonymized identification (ID) numbers. ** = P <
0.01; **** = P < 0.0001.
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Allelic expression differences identified at 8
SNPs by luciferase analysis. For these 39 SNPs, each
allele was cloned into a pGL3-promoter plasmid (with
multiple SNPs cloned together if they were <200 bp
apart) and relative luciferase activity was compared in
2 human cell lines, SW1353 chondrosarcoma cells and
HEK 293 cells. The former was chosen because of its
chondrocyte origin, and the latter because it abundantly
expresses ALDH1A2.
Six constructs encompassing a total of 8 SNPs
displayed significant allelic differences in transcriptional
activity (P < 0.05) (Figures 5A and B). These SNPs
were rs4646636, rs12915901, rs4646563, and rs4646586,
which correlated with rs3204689, and rs11071365,
rs11071366, rs4646571, and rs4646572, which correlated
with rs4238326.
Of the 8 SNPs, rs12915901 was particularly note-
worthy in that both the A and G alleles of this SNP
acted as an enhancer in both cell types (normalized
luciferase activity >1.0), with the A allele (equivalent to
the risk-conferring C allele of rs3204689) showing
lower expression relative to the non-risk G allele in
both cell types. The relative reduction in expression of
the risk allele observed for rs12915901 was 15% in
SW1353 cells and 14% in HEK 293 cells. These reduc-
tions are comparable to those observed in OA patient
cartilage (28%), fat pad (14%), and bone (15%) for
the C allele of rs3204689 (Figure 2). As such,
rs12915901 recapitulated the AEI seen in OA patients.
The additional 7 SNPs that displayed allelic differences
in transcriptional activity did not meet the same criteria
as met by rs12915901.
EMSA characterization of differential allelic
binding at rs12915901. We used EMSAs to character-
ize protein complex binding to each of the 8 positive
SNPs that emerged from our luciferase analysis. This
analysis revealed differential allelic binding of 2 protein
complexes to rs12915901 (results in SW1353 cells in
Figure 6A; results in HEK 293 cells in Supplementary
Figure 3A, available on the Arthritis & Rheumatology
web site at http://onlinelibrary.wiley.com/doi/10.1002/
art.40545/abstract). We found no consistent allelic dif-
ferences in protein complex binding for the other 7
SNPs analyzed. The 2 rs12915901 complexes bound
almost exclusively to the non-risk G allele of the SNP,
with the higher molecular weight complex competing
much less efficiently with the A allele than with the G
allele competitor (Figure 6B).
A search of the online databases JASPAR (http://
jaspar.genereg.net) and UniProbe (http://the_brain.bwh.
harvard.edu/uniprobe/) identified the Ets family of tran-
scription factors as potentially binding to rs12915901 and
its flanking sequence, but only for the non-risk G allele:
the highly conserved Ets DNA binding domain is
50-GGAA-30, which is intact for the G allele of rs12915901
but is abolished in the A allele, with the sequence chang-
ing to 50-GAAA-30 (underline indicates the rs12915901
base).
This hypothetical loss of Ets binding was consis-
tent with our EMSA data, in that the 2 protein com-
plexes bind to the G allele but not the A allele of the
SNP. We therefore used an Ets competitor sequence in
our EMSA. This competed very efficiently for binding
to the 2 protein complexes, implying that they do
Figure 5. Luciferase reporter analysis of single-nucleotide polymorphism (SNP) alleles. Four SNPs correlating with rs3204689 (A) and 2 SNP pairs
correlating with rs4238326 (B) demonstrated allelic expression differences in SW1353 and HEK 293 cells. Values are plotted as the mean  SEM
normalized luciferase activity from 6 biologic repeats, each with 6 technical repeats. For each SNP, the osteoarthritis risk–associated allele is shown
as light gray–shaded bars. The horizontal dashed line indicates no difference in expression relative to the Renilla transfection control (normalized
luciferase activity value of 1.0). P values were calculated using a Mann-Whitney 2-tailed exact test. * = P < 0.05; ** = P < 0.01; *** = P < 0.001.
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contain at least 1 Ets transcription factor (Figure 6B
and Supplementary Figure 3B, http://onlinelibrary.wiley.
com/doi/10.1002/art.40545/abstract). A random competi-
tor sequence had no effect (data not shown). Ets is one
of the largest family of transcription factors, with 29 Ets
genes in humans. Using our RNA-seq data, we deter-
mined that the majority of these Ets transcription fac-
tors were expressed in cartilage.
DISCUSSION
Retinoic acid plays a crucial role in organism
development (24), via its regulatory effects on chondro-
genesis and osteogenesis (25). Its synthesis involves the
oxidation of retinaldehyde to retinoic acid. This step is
catalyzed by the RALDH enzymes, of which there are 3
in humans (RALDH1, RALDH2, and RALDH3), each
coded for by a separate gene (ALDH1A1, ALDH1A2,
and ALDH1A3). RALDH2/ALDH1A2 is pivotal, with
knockout of the mouse ortholog being lethal (24).
A 2014 report discussing an association with OA
of SNPs at the ALDH1A2 locus (6) was the first occasion
in which the retinoic acid pathway had been associated
with OA at a genome-wide significance level, and those
findings highlighted the fact that a molecule key to early
postnatal development can have an impact on a disease
that tends to develop in older individuals. That prior
report contained a number of features common in OA
genetic studies: 1) the signal is to a gene involved in a
regulatory pathway; 2) the functional effect of the
genetic susceptibility is on gene expression; and 3) the
signal is not a risk factor for disease at all skeletal sites
examined (2,4,5).
We set out to replicate and expand upon the
findings included in the 2014 study. We confirmed that
the risk-conferring C allele of rs3204689 correlated
with reduced expression of ALDH1A2 in cartilage, and
demonstrated that this effect was common in the fat
pad and bone of OA patients, albeit to a lower degree.
AEI was less common in the synovium examined. Our
data suggest that the functional consequence of the
genetic risk is not uniform across joint tissues, with car-
tilage being the major target tissue. The fact that carti-
lage showed a more pronounced AEI when we studied
several joint tissue sites from the same individual sug-
gests that nongenetic modulators have a role. We have
previously demonstrated that ALDH1A2 is subject to
an mQTL that correlates with the association signal
(23). A detailed analysis of DNA CpG methylation and
ALDH1A2 AEI in multiple joint tissues from the same
donor is clearly merited.
We examined osteochondral tissue from patients
with hand OA who had undergone a trapeziectomy. Sev-
ere thumb OA was one of the clinical phenotypes for
which an association with ALDH1A2 was demonstrated
in the 2014 report. In the present study, we observed sta-
tistically significant AEI in the osteochondral tissue,
confirming, for the first time, that the risk allele at this
locus correlates with decreased expression of ALDH1A2
in the trapezium of patients with hand OA.
Our RNA-seq data revealed reduced expression
of ALDH1A2 in OA hip cartilage compared to non-OA
Figure 6. Electrophoretic mobility shift assay (EMSA) analyses of expression of the rs12915901 G and A alleles in SW1353 cells. A, Increasing
concentrations of unlabeled G allele and the A allele competitor were added to the EMSA reactions containing cell nuclear extract and a G or A
allele probe. B, Increasing concentrations of an unlabeled Ets competitor were added to the EMSA reaction containing a G allele or an A allele
probe. Arrows indicate 2 complexes binding with much greater affinity to the G allele than to the A allele.
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hip cartilage. Reduction in expression in OA cartilage,
combined with carriage of 1 or 2 copies of the low-
expressing C allele of rs3204689, may be the risk-
conferring scenario. In the same RNA-seq data set, we
observed differential expression of several retinoic acid–
related genes. This implies that a systemic alteration in
the activity of the retinoic acid pathway occurs in OA.
We are not aware of any reports that have discussed a
significant association of any of the other investigated
retinoic acid genes with OA, but an analysis of these
genes as candidate genes may be worthwhile.
A functional role of retinoic acid and retinoic acid
receptors in the pathogenesis of OA has been described.
Increased concentrations of retinoic acid receptor
ligands were previously reported in synovial fluid samples
extracted from patients with OA as compared to non-OA
controls (26). These increased concentrations of retinoic
acid metabolites and derivatives are suggested to be
detrimental to cartilage through the stimulation of
catabolic processes in chondrocyte explant cultures.
Paradoxically, our data suggest that decreased ALDH1A2
expression, and, by extrapolation, decreased retinoic
acid availability, may also compromise cartilage
integrity through modulation of SOX9 expression. The
catabolic effects of altered retinoic acid levels in carti-
lage perhaps suggest that the tight regulation of retinoic
acid production during development is also critical for
the long-term maintenance of healthy cartilage.
The results of our studies utilizing treatment of
chondrocytes with actinomycin D suggest that the alter-
ations in allelic expression occur as a result of the
effects on the rate of transcription rather than on tran-
script stability, while our knockdown of ALDH1A2
resulted in the reduced expression of several genes,
including the gene coding for the key chondrogenic
transcription factor SOX9. A recent report highlighted
the finding that ALDH1A2 expression is a positive
determinant of SOX9 expression in chondrocytes (27),
thereby supporting our own observations.
Our in silico and in vitro analyses of SNPs
correlating with the OA association signal identified the
ALDH1A2 intronic SNP rs12915901 as a SNP exhibiting
differences in allelic activity that matched the allelic
effects seen in our patient-based studies. Our EMSA anal-
yses implicated the Ets family of transcription factors as
positive regulators of expression. Members of this family
have previously been reported to have a role in OA via
regulation of the expression of chondrogenic genes
(28,29). Detailed analysis of these Ets transcription fac-
tors in the context of the ALDH1A2 association signal
and ALDH1A2 expression is now warranted.
We analyzed several samples of OA trapezieum
tissue, but the vast majority of our tissue came from hip
or knee arthroplasties, reflecting the small volume of
hand OA surgical procedures undertaken relative to hip
and knee procedures. In our quantification of ALDH1A2
expression, the trapezium samples displayed relatively
low levels compared to the hip and knee cartilage sam-
ples. We posit therefore that where the expression of the
gene is already low, as in the hand, that joint may not be
able to tolerate further reduction in expression brought
about by carriage of the risk allele.
In conclusion, we have characterized the eQTL
operating on ALDH1A2 in multiple joint tissue sites,
including trapezium samples obtained from patients
with hand OA. We highlight the functional effect of
decreased ALDH1A2 expression in human chondro-
cytes and show that retinoic acid–related genes are dif-
ferentially expressed between OA diseased cartilage
and non-OA control cartilage. Our findings prioritize a
SNP as a functional variant potentially responsible for
the modulation of ALDH1A2 expression. Experiments
building on our findings can now be planned to
develop strategies to mitigate the effect of the risk of
OA conferred by ALDH1A2.
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